## JC10 Rec'd PCT/PTO 09 JUN 2005

<u> </u>								
FORM PTO-1390(modified) U.S. DEPARTMENT OF COMM (REV 10-95)	ATTORNEY'S DOCKET NUMBER  29724							
TRANSMITTAL LETTER TO THE UNITED STATES		U.S. APPLICATION NO. (IF KNOWN), SEE 37 CFR						
DESIGNATED/ELECTED OFFICE	COO/EO/US) CONCERNING							
A FILING UNDER 35 U.S.C., 371		10/538171						
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED						
PCT/IL03/01057	11 December 2003	12 December 2002						
TITLE OF INVENTION  GLYCOGEN SYNTHASE KINASE-3 INHIBITORS								
APPLICANT(S) FOR DO/EO/US								
Hagit ELDAR-FINKELMAN								
Applicant herewith submits to the United States Designated/Elected Office (DO/EO.US) the following items and other information:								
Approant herewith suching to the Chited Su	nes Designated Elected Office (DO/EO	.03) the following items and other information.						
1. In This is a FIRST submission of items	concerning a filing under 35 U.S.C. 37	1.						
2.   This is a SECOND or SUBSEQUEN								
3. A This is an express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay								
		2. 371(b) and PCT Articles 22 and 39(1).						
4. 🗷 A proper Demand for International Preliminary Examination was made by the 19 <sup>th</sup> month from the earliest claimed priority date.								
5. A copy of the International Application	ion as filed (35 U.S.C. 371(3)(2)	-						
a.  is transmitted herewith (required only if not transmitted by the International Bureau).								
b. E has been transmitted by the	International Bureau.	,						
c. $\square$ is not required, as the application was filed in the United States Receiving Office (RO/US).								
6. A translation of the International Application into English (35 U.S.C. 371(3)(2).								
7. Z A copy of the International Search Report (PCT/ISA/210).								
8.  Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)								
a.   are transmitted herewith (required only if not transmitted by the International Bureau).								
b.  have been transmitted by the International Bureau.								
c. $\square$ have not been made; however, the time limit for making such amendments has NOT expired.								
d.  have not been made and will not be made.								
9.   A translation of the amendments to the claims under PCT Article 19(35 U.S.C. 371(c)(3)).								
10. An <u>unsigned</u> oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).								
11. 🗵 A copy of the International Preliminary Examination Report (PCT/IPEA/409).								
12. A translation of the annexes to the In	iternational Preliminary Examination Re	eport under PCT Article 36 (35 U.S.C. 371(c)5)).						
Items 13 to 18 below concern document(s)	of information included:							
13. An Information Disclosure Statemen								
14. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.								
15. A FIRST preliminary amendment.	ng. A separate cover sheet in compitant	c with 57 Cl R 5.26 and 5.51 is included.						
A SECOND or SUBSEQUENT pre	eliminary amendment							
16. ☐ A substitute specification.	Animary amendment.							
17.   A change of power of attorney and/o	or address letter	·						
18. ☐ Certificate of Mailing by Express Ma		•						
		ntical to the written (on paper or compact disc)						
sequence listing	order in comparer readucto form to race	(on paper or compact close)						
I = =	OUEST: PRELIMINARY AMENDMEN	T: FLOPPY DISC WITH SEQUENCE LISTING						
20.  Other items or information: <u>PCT REQUEST; PRELIMINARY AMENDMENT; FLOPPY DISC WITH SEQUENCE LISTING</u> 21.  28 85 pages of specification (including Abstract page)								
22. \(\overline{\text{\text{\sigma}}}\) sheets of drawings								
23. \(\mathbb{Z}\) 5 pages of sequence listing								
24. 🗵 <u>96</u> total pages								

U.S. APPLICATION NO (IE KNOWN), See 37 CFR, 1

INTERNATIONAL APPLICATION NO. PCT/IL03/01057

ATTORNEY'S DOCKET NUMBER

29724

## THE FILING FEE HAS BEEN CALCULATED AS SHOWN BELOW:

FOR:	Column 1 Column 2 No. FILED No. EXTRA		SMALL ENTITY		OTHER THAN A SMALL ENTITY	
		1.0.21114	RATE	<i>FEE</i>	RATE	FEE
Basic National Stage Fee				\$ 150		\$ 300
National Stage Search Fee				\$ 250		\$ 500
National Stage Examination Fee				\$ 100		\$ 200
National Stage Application Size Fee (Per 50 Pages Over 100)			x \$ 125	\$	x \$250	\$
Multiple Dependent Claim			x \$ 180	\$	x \$ 360	\$
Total Claims*	73 - 20=	53	x \$ 25	\$ 1325	x \$50	\$
Independent Claims*	3 - 3=	0	x \$100	\$	x \$200	\$
* (If the difference in Column 1 is less than "0", enter "0" in Column 2)			TOTAL	\$1825	TOTAL	<u>\$</u>

×	lease charge my deposit account No. 50-1407 in the amount of \$1,825.00
	A duplicate copy of this sheet is enclosed

A duplicate copy of this sheet is enclosed.

The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No 50-1407. A duplicate copy of this sheet is enclosed.

- Any additional filing fees required under 37 CFR 1.16.
- Any patent application processing fees under 37 CFR 1.17.
- The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to deposit Account No. 50-1407. A duplicate copy of this sheet is enclosed.
  - Any patent application processing fees under 37 CFR 1.17.
  - Any filing fees under 37 CFR 1.16 for presentation of extra claims.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Martin Moynihan C/O ANTHONY CASTORINA SUITE 207 2001 JEFFERSON DAVIS HIGHWAY ARLINGTON, VIRGINIA 22202, USA SIGNATURE /

Martin Moynihan

NAME

40,338

REGISTRATION NUMBER

7 June 2005

**DATE**